Cargando…
Evaluation of Macitentan in Patients With Eisenmenger Syndrome: Results From the Randomized, Controlled MAESTRO Study
BACKGROUND: Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eisenmenger Syndrome to Restore Exercise...
Autores principales: | Gatzoulis, Michael A., Landzberg, Michael, Beghetti, Maurice, Berger, Rolf M., Efficace, Michela, Gesang, Sophie, He, Jian’guo, Papadakis, Kelly, Pulido, Tomás, Galiè, Nazzareno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314514/ https://www.ncbi.nlm.nih.gov/pubmed/30586694 http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033575 |
Ejemplares similares
-
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022) -
Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017) -
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017) -
Eisenmenger syndrome
por: de Campos, Fernando Peixoto Ferraz, et al.
Publicado: (2017) -
Eisenmenger Syndrome in Pregnancy
por: Yuan, Shi-Min
Publicado: (2016)